/
MBIO
$0.59-$0.01 (-1.88%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$4.6M
8M shares
52-week range
$0.52 – $1.85
5% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-1994.41
Mustang Bio, Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
www.mustangbio.com- Employees
- 4
- IPO / List date
- Aug 22, 2017
- HQ
- WALTHAM, MA
Held by traders on TradeandTell
No one on the platform currently holds MBIO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 11,800 | $17.9K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-01-16 | 1-for-50reverse |
| 2023-04-04 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded MBIO yet.
